MR-Guided Radiation Therapy for Endometrial Cancer

(ADAPT-EC Trial)

This trial tests a new type of radiation therapy for people with endometrial cancer. The treatment, called MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT), uses an MRI machine to guide and adjust radiation. This approach could enhance safety and effectiveness by protecting nearby healthy organs. It targets individuals diagnosed with endometrial cancer who require additional pelvic radiation therapy after surgery. Participants must not have had previous pelvic radiation and must be able to complete specific health questionnaires. As an unphased trial, this study allows patients to contribute to innovative research that could improve future cancer treatments.

Research has shown that MR-guided adaptive pelvic IMRT, a type of radiation therapy, is generally safe and well-tolerated. One study found that patients who received this treatment experienced manageable side effects and reported positive experiences, with any long-term side effects deemed acceptable.

Another study demonstrated that this radiation therapy accurately targets cancer cells while protecting nearby healthy organs, reducing the risk of harm. This precision minimizes unwanted side effects, which is crucial for patient comfort and safety.

Unlike the traditional radiation therapy for endometrial cancer, which typically involves a fixed radiation dose plan, MR-guided adaptive pelvic IMRT offers a personalized approach. This method uses MRI guidance to tailor the radiation dose to the patient's anatomy on a daily basis, allowing for precise targeting of the cancer while sparing surrounding healthy tissues. Researchers are excited about this treatment because it promises enhanced precision and potentially fewer side effects, which could lead to better outcomes for patients. Additionally, incorporating vaginal brachytherapy as needed provides a versatile treatment strategy that can be adjusted according to individual patient needs.

Research has shown that MRI-guided radiation therapy for treating endometrial cancer appears promising. This trial will evaluate MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) as an experimental treatment. This method focuses the radiation more precisely on the cancer, reducing the impact on nearby healthy organs. Some studies have improved the accuracy of targeting the cancer in 82–100% of treatments. Specifically, one study found that using this type of radiation therapy after surgery is safe and effective for patients with endometrial cancer. Additionally, MRI-guided therapy has resulted in the complete disappearance of tumors in some patients. Overall, these findings suggest that this treatment could effectively manage endometrial cancer.¹⁴⁵⁶⁷